A library of 16 3-benzyl-N
1-substituted
quinoxalin-2-ones was synthesized as N
1-substituted quinoxalines and quinoxaline-triazole hybrids via click
reaction. These compounds were tested for their anticancer activity
via MTT assay on HCT-116 and normal colonocyte cell lines to assess
their cytotoxic potentials and safety profiles. Overall, compounds 6, 9, 14, and 20 were
found to be promising anticolorectal cancer agents; they exhibited
remarkable cytotoxicity (IC50 0.05–0.07 μM)
against HCT-116 cells within their safe doses (EC100) on normal colon
cells. Their pronounced anticancer activities were observed as severe
morphological alterations and shrinkage of the treated cancer cells.
Besides, qRT-PCR analysis was conducted showing the potential of the
promising hits to downregulate HIF-1a, VEGF, and BCL-2 as well as
their ability to enhance the expression of proapoptotic genes p21,
p53, and BAX in HCT-116 cells. In silico prediction
revealed that most of our compounds agree with Lipinski and Veber
parameters of rules, in addition to remarkable medicinal chemistry
and drug-likeness parameters with no CNS side effects. Interestingly,
docking studies of the compounds in the VEGFR-2’ active site
showed significant affinity toward the essential amino acids, which
supported the biological results.